PM
UROV

Prosight Management’s Urovant Sciences Ltd. UROV Stock Holding History

Prosight Management’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-102,657
Closed -$972K – 49
2019
Q3 		$972K Sell
102,657
-39,963
-28% -$347K 0.54% 32
2019
Q2 		$1.13M Buy
142,620
+42,750
+43% +$351K 0.57% 30
2019
Q1 		$1M Buy
+99,870
New +$1.02M 0.44% 34

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Prosight Management's UROV Position: Q4 2019 in Review

Prosight Management sold out of Urovant Sciences Ltd. (UROV) in Q4 2019, closing a stake of 102,657 shares — an estimated $972K sold.

Prosight Management first reported a position in UROV in Q1 2019 and held it in 3 quarters. The position peaked at $1.13M in Q2 2019. 25 funds tracked by Wall St. Rank hold UROV as of Q4 2019.

  • Prosight Management reported no remaining Urovant Sciences Ltd. position as of Q4 2019 after selling out during the quarter.
  • Prosight Management sold 102,657 Urovant Sciences Ltd. shares in Q4 2019, an estimated $972K.
  • Prosight Management first reported a position in Urovant Sciences Ltd. in Q1 2019 and held it in 3 quarters.
  • Prosight Management's Urovant Sciences Ltd. position peaked at $1.13M in Q2 2019.
  • 25 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2019.

Based on Prosight Management's 13F filing for Q4 2019, filed 14 Feb 2020.